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COMMENT   
Oxidative stresses and dys-homeostasis of metal 
metabolism, especially Cu and Zn, in association 
with intracellular protein-misfolding processes of 
amyloid beta (Aβ) peptides, are major hallmarks in 
the brains of Alzheimer patients.
1
 Currently, no 
medications for etiological treatments of Alzheimer’s 
disease (AD), implying the recovery and modulation 
of metal ion homeostasis inside the cell, are so far 
available. Several therapeutic strategies and nearly all 
medications used or suggested, aim at the treatment 
of AD symptoms only and are not focused on the 
origin of this cureless chronically progressive 
neurodegenerative disease.
1
 
 
The medical community, including the 
pharmaceutical industry, as well as AD patients have 
become aware of the well-known antioxidant effects 
of ancient herbal medications, e.g., Ginkgo biloba 
leaf extracts.
2
 The mechanisms of action are thought 
to reflect the action of their major biologically active 
compounds, namely flavonoids and terpenoids. 
Exemplary, the flavonol quercetin was found to 
interact with Cu
2+
 and Fe
3+
 ions.
3
 However, it is 
evident that commercially available medicinal plant 
extracts have no predictable and clinically significant 
benefit for people with dementia or cognitive 
impairment.
2
 Furthermore, the results from the study 
of He and colleagues suggested that high doses of 
herbal remedies can even be toxic to cells.
4
 
 
Thus Ginkgo biloba extracts may induce unwanted 
side-effects and may also lack specificity as to the 
binding of Cu
+
 and Zn
2+
 ions in the cytoplasm.
3-5
 
These extracts can neither reduce metal-based 
oxidative stress nor contribute to the homeostatic 
control of those metal ions in human cells. Yet, for 
the recovery and modulation of metal ion 
homeostasis in the treatment of Alzheimer's disease, 
we have proposed another class of pharmacologically 
active plant ingredients as antioxidant: plant copper 
chaperones for superoxide dismutase (pCCS).
5,6
 
These proteins have the ability to bind and deliver 
Cu
+
 ions specifically and to normalize Cu/Zn 
superoxide dismutase activity via specific protein-
protein interactions in the brain and body of AD 
patients.
5,6
 We have begun to evaluate the relative 
biochemical impact of pCCS in patients and probands 
using state-of-the-art biochemical techniques.
5,6
 We 
believe that this promising approach might provide 
fundamental understanding of the complex 
physiological processes that may lead to oxidative 
stresses in protein-misfolding diseases and help to 
develop a novel generation of herbal drugs for 
Alzheimer's disease. 
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